PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30116631-7 2018 Then we tested which of cell signal pathways regulating the production of IL-6 were activated when we added MG132 into the medium by Western blot and electrophoretic mobility shift assays (EMSA). benzyloxycarbonylleucyl-leucyl-leucine aldehyde 108-113 interleukin 6 Homo sapiens 74-78 12067409-0 2002 Proteasome inhibitor MG-132 enhances the expression of interleukin-6 in human umbilical vein endothelial cells: Involvement of MAP/ERK kinase. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 21-27 interleukin 6 Homo sapiens 55-68 12067409-4 2002 MG-132 increased the expression of IL-6 mRNA and protein;and this effect was abolished by the pretreatment of the cells with U0126, an inhibitor of MAP or ERK kinases (MEK 1/2). benzyloxycarbonylleucyl-leucyl-leucine aldehyde 0-6 interleukin 6 Homo sapiens 35-39 12067409-7 2002 We conclude that a protease inhibitor MG-132 upregulates IL-6 expression in vascular endothelial cells, at least in part, through the activation of MEK 1/2. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 38-44 interleukin 6 Homo sapiens 57-61 11104703-5 2000 However, pretreatment with the proteasome inhibitor MG132 under conditions that prevented the IL-1beta-dependent activation of the nuclear factor NF-kappaB also blocked the inhibitory effect of IL-1beta on IL-6-activated STAT1. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 52-57 interleukin 6 Homo sapiens 206-210 16954375-9 2006 Similarly, the proteasome inhibitor MG132 stabilized interleukin-6 mRNA probably through an increase of AUF1 levels. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 36-41 interleukin 6 Homo sapiens 53-66 10748190-6 2000 UV-induced IL-6 release is mediated via NFkappaB since the NFkappaB inhibitor MG132 or transfection of cells with a super-repressor form of the NFkappaB inhibitor IkappaB reduced IL-6 release. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 78-83 interleukin 6 Homo sapiens 11-15 10748190-6 2000 UV-induced IL-6 release is mediated via NFkappaB since the NFkappaB inhibitor MG132 or transfection of cells with a super-repressor form of the NFkappaB inhibitor IkappaB reduced IL-6 release. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 78-83 interleukin 6 Homo sapiens 179-183 10611258-6 2000 The proteasome inhibitor MG132 (0.3 and 3 micromol/l) also caused a dose-dependent decrease in IL-1alpha and TNFalpha-stimulated IL-6 (P < 0.001 and P < 0.001 respectively) and leukaemia inhibitory factor (LIF) (P < 0. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 25-30 interleukin 6 Homo sapiens 129-133 30116631-9 2018 Results: MG132 decreased the secretion of MCP-1 in the culture medium of RPE, but it increased the expression of IL-6 mRNA in RPE and IL-6 protein level in the culture medium of RPE. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 9-14 interleukin 6 Homo sapiens 113-117 30116631-9 2018 Results: MG132 decreased the secretion of MCP-1 in the culture medium of RPE, but it increased the expression of IL-6 mRNA in RPE and IL-6 protein level in the culture medium of RPE. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 9-14 interleukin 6 Homo sapiens 134-138 30116631-11 2018 More importantly, the effect of MG132 on upregulating the levels of IL-6 was inhibited by SB203580, an inhibitor of P38 MAP kinases. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 32-37 interleukin 6 Homo sapiens 68-72 30116631-12 2018 But the JNK inhibitor, SP600125, cannot prevent the effect of upregulating the levels of IL-6 by MG132 in the RPE culture medium. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 97-102 interleukin 6 Homo sapiens 89-93 30116631-13 2018 Conclusions: We concluded that the proteasome inhibitor, MG132, upregulates IL-6 production in RPE cells through the activation of P38 MAPKs. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 57-62 interleukin 6 Homo sapiens 76-80 22977658-5 2012 Moreover, we found that the proteasome inhibitor MG132 could inhibit IL-6/TGF-beta-mediated downregulation of FOXP3 protein, which reveals a potential pathway for modulating Treg activity by preventing FOXP3 degradation during inflammation. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 49-54 interleukin 6 Homo sapiens 69-73 20043958-6 2010 Investigating the effect of MG-132 on secretion of the cytokine IL-6 we show that while short-term pretreatment with MG-132 (30min) partially reduced TNFalpha-induced IL-6 via inhibition of IkappaB-alpha degradation and the NF-kappaB pathway, longer-term proteasome inhibition (up to 24h) robustly upregulated MKP-1 and was temporally correlated with repression of p38-mediated IL-6 secretion from ASM cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 28-34 interleukin 6 Homo sapiens 64-68 20043958-6 2010 Investigating the effect of MG-132 on secretion of the cytokine IL-6 we show that while short-term pretreatment with MG-132 (30min) partially reduced TNFalpha-induced IL-6 via inhibition of IkappaB-alpha degradation and the NF-kappaB pathway, longer-term proteasome inhibition (up to 24h) robustly upregulated MKP-1 and was temporally correlated with repression of p38-mediated IL-6 secretion from ASM cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 117-123 interleukin 6 Homo sapiens 64-68 20043958-6 2010 Investigating the effect of MG-132 on secretion of the cytokine IL-6 we show that while short-term pretreatment with MG-132 (30min) partially reduced TNFalpha-induced IL-6 via inhibition of IkappaB-alpha degradation and the NF-kappaB pathway, longer-term proteasome inhibition (up to 24h) robustly upregulated MKP-1 and was temporally correlated with repression of p38-mediated IL-6 secretion from ASM cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 117-123 interleukin 6 Homo sapiens 167-171 20043958-6 2010 Investigating the effect of MG-132 on secretion of the cytokine IL-6 we show that while short-term pretreatment with MG-132 (30min) partially reduced TNFalpha-induced IL-6 via inhibition of IkappaB-alpha degradation and the NF-kappaB pathway, longer-term proteasome inhibition (up to 24h) robustly upregulated MKP-1 and was temporally correlated with repression of p38-mediated IL-6 secretion from ASM cells. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 117-123 interleukin 6 Homo sapiens 167-171